hypertrophic cardiomyopathy
3 stories
-
healthAficamten Superior to Metoprolol for Hypertrophic Cardiomyopathy Exercise Performance
New Phase III trial data shows the cardiac myosin inhibitor Aficamten significantly improves exercise capacity over the standard therapy, Metoprolol, in patients with obstructive hypertrophic cardiomyopathy.
-
healthNew Study Links Heart Failure to Poor Outcomes in Hypertrophic Cardiomyopathy
Machine learning study identifies heart failure with preserved ejection fraction in hypertrophic cardiomyopathy patients as a key predictor of adverse outcomes.
-
healthFrom HCM Diagnosis to Heart Transplant: A Survivor's Journey
A powerful story of resilience through hypertrophic cardiomyopathy, implantable defibrillators, and ultimately, a successful heart transplant.